このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

ImmunityBio マネジメント

マネジメント基準チェック /44

ImmunityBio'sの CEO はRich Adcockで、 Oct2020年に任命され、の在任期間は 3.67年です。の年間総報酬は$ 1.16Mで、 68.8%給与と31.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.035%を直接所有しており、その価値は$ 1.42M 。経営陣と取締役会の平均在任期間はそれぞれ3.3年と3.8年です。

主要情報

Rich Adcock

最高経営責任者

US$1.2m

報酬総額

CEO給与比率	68.8%
CEO在任期間	3.7yrs
CEOの所有権	0.04%
経営陣の平均在職期間	3.3yrs
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

CEO報酬分析

ImmunityBio の収益と比較して、Rich Adcock の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$601m
Dec 31 2023	US$1m	US$796k	-US$583m
Sep 30 2023	n/a	n/a	-US$458m
Jun 30 2023	n/a	n/a	-US$473m
Mar 31 2023	n/a	n/a	-US$430m
Dec 31 2022	US$4m	US$791k	-US$417m
Sep 30 2022	n/a	n/a	-US$400m
Jun 30 2022	n/a	n/a	-US$376m
Mar 31 2022	n/a	n/a	-US$370m
Dec 31 2021	US$29m	US$765k	-US$347m
Sep 30 2021	n/a	n/a	-US$323m
Jun 30 2021	n/a	n/a	-US$301m
Mar 31 2021	n/a	n/a	-US$264m
Dec 31 2020	US$843k	US$141k	-US$222m

報酬と市場: Richの総報酬 ($USD 1.16M ) は、 US市場 ($USD 6.80M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Richの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Rich Adcock (55 yo)

3.7yrs

在職期間

US$1,156,903

報酬

Mr. Richard Gerald Adcock, also known as Rich, has been the President of ImmunityBio, Inc. since March 05, 2021 and serves as its Director since March 29, 2021. He has been the Chief Executive Officer of I...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Patrick Soon-Shiong	Executive Chairman of the Board and Global Chief Scientific & Medical Officer	9.6yrs	US$865.34k	42.1% $ 1.8b
Richard Adcock	President	3.7yrs	US$1.16m	0.035% $ 1.5m
David Sachs	Chief Financial Officer	4.9yrs	US$1.06m	0.027% $ 1.2m
Barry Simon	Chief Corporate Affairs Officer & Director	3.3yrs	データなし	0.45% $ 19.5m
Leonard Sender	Chief Operating Officer	4.3yrs	データなし	データなし
Regan Lauer	Chief Accounting Officer	2.6yrs	データなし	0.014% $ 587.7k
Enrique Diloné	Chief Technology Officer	1.4yrs	データなし	データなし
Jason Liljestrom	General Counsel & Corporate Secretary	3yrs	データなし	データなし
Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy	4.3yrs	データなし	データなし
Sandeep Reddy	Chief Medical Officer	3.8yrs	データなし	データなし
Hans Klingemann	Chief Science Officer of Cellular	no data	データなし	データなし
Elizabeth Gabitzsch	Senior Vice President of Product Development & Vaccine Programs	less than a year	データなし	データなし

3.3yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: IBRXの経営陣は経験豊富であると考えられます ( 3.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Patrick Soon-Shiong	Executive Chairman of the Board and Global Chief Scientific & Medical Officer	9.6yrs	US$865.34k	42.1% $ 1.8b
Richard Adcock	President	3.3yrs	US$1.16m	0.035% $ 1.5m
Barry Simon	Chief Corporate Affairs Officer & Director	17.4yrs	データなし	0.45% $ 19.5m
Christobel Selecky	Independent Director	3.8yrs	US$470.00k	0% $ 0
Wesley Clark	Independent Director	3.3yrs	US$465.00k	0.0012% $ 50.0k
Michael Blaszyk	Independent Director	8.9yrs	US$510.00k	0.038% $ 1.7m
John Brennan	Independent Director	3.3yrs	US$472.50k	0.0036% $ 155.5k
Cheryl Cohen	Lead Independent Director	5yrs	US$506.25k	0.029% $ 1.2m
Linda Maxwell	Independent Director	3.3yrs	US$487.50k	0% $ 0

3.8yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: IBRXの取締役会は経験豊富であると考えられます ( 3.8年の平均在任期間)。

ImmunityBio マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

Insufficient new directors

ImmunityBio, Inc. Appoints Enrique Diloné as Chief Technology Officer, Effective August 14, 2023

Independent Director recently bought US$71k worth of stock

ImmunityBio, Inc., Annual General Meeting, Jun 13, 2023

President exercised options and sold US$183k worth of stock

Recent updates

ImmunityBio, Inc. Announces the Initial Treatment of Multiple Patients in the United States to Receive Therapy with ANKTIVA

ImmunityBio: Anktiva's Launch Demands A Reassessment

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

Consensus revenue estimates increase by 639%, EPS downgraded

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle

Insufficient new directors

Consensus revenue estimates increase by 25%

No longer forecast to breakeven

New minor risk - Profitability

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio Announces Data from A Phase 1 Pilot Study

ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise

New major risk - Share price stability

ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Forecast to breakeven in 2026

ImmunityBio: Buy Low Now Vs. Buy High Later

Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes (PROs) of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG

Consensus revenue estimates decrease by 54%, EPS upgraded

New major risk - Financial position

ImmunityBio, Inc. Announces First Data for Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-Tumor Activity

ImmunityBio, Inc. Announces U.S. Food and Drug Administration Accepts its BLA Resubmission as Complete and Sets New PDUFA Date

New major risk - Share price stability

ImmunityBio, Inc. Announces Biological License Application Resubmission for N-803 in BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

New major risk - Shareholder dilution

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

Consensus revenue estimates increase by 20%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jakubowitz Law Reminds Immunitybio Shareholders of A Lead Plaintiff Deadline of August 29, 2023

ImmunityBio, Inc. Appoints Enrique Diloné as Chief Technology Officer, Effective August 14, 2023

ImmunityBio, Inc. Announces Findings from a Phase 1 Study Showing Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells

Pomerantz Law Firm Announces the Filing of a Class Action Against ImmunityBio, Inc. and Certain Officers – IBRX

Independent Director recently bought US$71k worth of stock

ImmunityBio, Inc., Annual General Meeting, Jun 13, 2023

ImmunityBio, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration Regarding Its Biologics License Application

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

President exercised options and sold US$183k worth of stock

ImmunityBio, Inc. announced that it expects to receive $50 million in funding

Price target decreased to US$9.00

High number of new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio: PDUFA Pending

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.23 loss in 2Q 2021)

ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain

Consensus forecasts updated

ImmunityBio, Inc. Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio, Inc. Announces Quilt Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer

ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission

ImmunityBio, Inc. Submits Biologics License Application for N-803 Plus Bcg for Patients with Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

First quarter 2022 earnings: EPS and revenues miss analyst expectations

ImmunityBio, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$20.00

High number of new directors

Immunitybio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

ImmunityBio: Extensive Pipeline, NDA Expected For Anktiva This Quarter

ImmunityBio, Inc. Announces Study Results That Further Demonstrate the Potential for Use of Memory-Like Cytokine-Enriched Natural Killer (m-ceNK) Cells for the Treatment of Cancer

ImmunityBio, Inc. Announces Study Results That Further Demonstrate the Potential for Use of Memory-Like Cytokine-Enriched Natural Killer (m-ceNK) Cells for the Treatment of Cancer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

ImmunityBio, Inc. Announces Positive Data from its Late-Stage Bladder Cancer Trial

President exercised options and sold US$159k worth of stock

ImmunityBio, Inc. Announces Promising Clinical Study Results for Kick and Kill HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy

ImmunityBio, Inc. Announces Interim Results in its Metastatic Pancreatic Cancer Trial

ImmunityBio: Company Leaves 2021 On A High-Note; Share Price Still Falls Flat

マネジメント基準チェック /44